How GLP-1 and GLP-1 + GIP medications work, what the research shows about related health conditions, and the nutrition, protein, hydration, training and lab topics that come up during a provider-guided weight program.
Other topics: Daily Wellness · Sexual Health · Hair & Skin
44 articles
Visceral fat is the fat stored deep around your abdominal organs, and it is more closely tied to heart and metabolic disease than total weight. A tape measure around your waist is a simple home check, and exercise can shrink visceral fat even when the scale barely moves.
Read articleGLP-1 results vary widely. In trials, most people reached at least 5 percent weight loss while a minority did not. Medication and dose, type 2 diabetes, staying on treatment and early response all help explain the spread.
Read article
You can travel, celebrate and eat out on a GLP-1 medication with some planning: keep medication in your carry-on and follow your pharmacy's storage instructions, order smaller portions, keep fluids up, and ask your prescriber how to handle timing changes.
Read article
An underactive thyroid can add modest weight and fatigue, so a TSH test is a sensible check if you have symptoms. Separately, GLP-1 labels warn against use with a personal or family history of medullary thyroid cancer or MEN 2, so share your full thyroid history.
Read articlePeople switch GLP-1 medications because of side effects, response, cost or access. There is no universal conversion chart, the labels advise against combining these drugs, and your prescriber sets the new starting point. Here are the questions worth asking.
Read article
Short sleep and ongoing stress both make weight harder to manage. In controlled studies, cutting sleep raised hunger and shifted weight loss away from fat, while extending sleep reduced daily calorie intake. Stress affects eating, activity, sleep and hormones.
Read articleThe first weeks on a GLP-1 usually mean a low starting dose that your prescriber raises gradually, a quieter appetite, and for many people mild to moderate digestive side effects. Knowing what is common and what to report makes the start easier.
Read articlePrediabetes means blood sugar is above normal but below the type 2 diabetes range, usually an A1C of 5.7 to 6.4 percent. Lifestyle change is the proven first step, and GLP-1 trials show added benefit in people who also have obesity.
Read articleOral and injectable semaglutide are the same molecule. The tablet is taken daily on an empty stomach with an absorption enhancer; the injection is weekly. Wegovy tablets are approved for weight reduction in adults, and trial averages for both forms were broadly similar.
Read articleObesity is treated as a chronic disease because body weight is defended by biology, its causes go well beyond willpower, and its health effects usually return when treatment stops. That is why care is framed as long-term management, not a short fix.
Read articleEating much less can make it hard to meet vitamin and mineral needs. A 2025 study of GLP-1 users found most fell short on vitamin D, iron, magnesium and potassium from food. Food-first choices and lab checks guided by a provider help.
Read articleA1c shows average blood sugar over 2 to 3 months, a lipid panel measures cholesterol and triglycerides, liver enzymes flag liver stress such as fatty liver, and eGFR estimates kidney filtering. Here is what each test means and the reference points public health sources use.
Read article
During the menopause transition, fat mass rises faster and lean mass starts to decline, even when the scale moves only slowly. Hormone therapy treats menopausal symptoms rather than weight, while GLP-1 medications, strength training and protein address weight and body composition.
Read articleLow-dose or "microdose" GLP-1 use means taking less than the labeled dose, or spacing doses further apart. It is off-label, no randomized trials have tested it, and current evidence is limited to rationale, small observational data and clinician experience.
Read article
Loose skin after major weight loss reflects lasting changes in the skin's collagen network, so creams, supplements and exercise cannot fully reverse it. Age, sun and smoking play a role; surgery is the only reliable removal option.
Read articleIn randomized trials, intermittent fasting produced about the same weight loss as ordinary calorie reduction. On a GLP-1 medication, which already lowers intake, adding a fasting window can make it harder to eat enough protein, so discuss it with your prescriber first.
Read articleGut bacteria clearly influence body weight in mice, but human evidence is far less certain. A fecal transplant trial in adults with obesity found no meaningful metabolic change, and probiotics have no FDA-approved health claims. Diet is the best supported lever.
Read articleExcess weight is a major driver of obstructive sleep apnea, and modest weight change shifts its severity. Zepbound (tirzepatide) became the first FDA-approved medication for moderate to severe sleep apnea in adults with obesity in December 2024.
Read articleThe 2023 international PCOS guideline says GLP-1 medications could be considered with lifestyle support to manage higher weight in adults with PCOS. PCOS-specific trials are still small and short, use for PCOS is off-label, and effective contraception is advised.
Read articleSemaglutide has shown kidney protection in large trials, most clearly in people with type 2 diabetes and chronic kidney disease. GLP-1 medications can also stress the kidneys if vomiting or diarrhea cause dehydration, so hydration and lab monitoring matter.
Read articleExtra body weight multiplies the load on your knees, and guidelines strongly recommend weight loss for knee osteoarthritis. In the STEP 9 trial, semaglutide plus counseling reduced knee pain scores more than counseling alone, though it is not approved for osteoarthritis.
Read articleGLP-1 medications are linked to a modestly higher rate of gallstones and gallbladder inflammation, partly because faster weight loss raises gallstone risk on its own. These events are uncommon, and knowing the warning signs helps you act early.
Read articleGLP-1 medications are not recommended during pregnancy, and ACOG advises considering stopping them 1 to 2 months before trying to conceive. Fertility can rise as weight changes, so effective contraception during treatment matters, and tirzepatide can reduce how well birth control pills work.
Read articleFatty liver disease linked to metabolic health is now called MASLD, and its inflammatory form is MASH. Weight loss is the core treatment, and Wegovy (semaglutide) gained FDA accelerated approval in 2025 for MASH with moderate to advanced scarring.
Read articleOzempic and Wegovy contain semaglutide; Mounjaro and Zepbound contain tirzepatide. Ozempic and Mounjaro are approved for type 2 diabetes, Wegovy and Zepbound for chronic weight management. Compounded versions are not FDA-approved.
Read article
An FDA review in 2026 found no increased risk of suicidal thoughts or behavior with GLP-1 medications, and the warning was removed from weight-management labels. Early research on alcohol cravings is promising but small, and a large Alzheimer's trial was negative.
Read articleIn major trials, semaglutide and tirzepatide lowered systolic blood pressure by about 5 to 7 mm Hg more than placebo on average, largely alongside weight loss. They are not blood pressure medications, and they can occasionally push pressure too low.
Read articleFood noise is a popular term for constant, intrusive thoughts about food. Research links it to food cue reactivity, which is shaped by appetite hormones that shift after weight loss, and GLP-1 medications act on brain areas that regulate appetite.
Read articlePhysical hunger builds with time since your last meal and is satisfied by most foods; emotional eating is driven by stress, mood or habit. Research links it to dieting, stress hormones and sleep, and small check-ins can help you tell the difference.
Read articleCompounded semaglutide and tirzepatide are not FDA-approved. The FDA declared both national shortages resolved by early 2025, so compounding is now limited mainly to patient-specific prescriptions under section 503A, and in 2026 the FDA proposed keeping both off the 503B bulks list.
Read articleWeight loss often brings a small drop in bone density, including with GLP-1 medications. Trials suggest regular exercise, especially resistance training, limits that loss, alongside enough calcium and vitamin D and screening when appropriate.
Read articleBMI is a quick screening number based on height and weight, but it cannot tell fat from muscle or show where fat sits. Waist size and waist-to-height ratio add information about abdominal fat, and body fat measures fill in the rest. Used together, they give a clearer picture.
Read articleSome compounded semaglutide and tirzepatide formulas add vitamin B12 or the amino acid glycine, partly for regulatory reasons and partly for hoped-for nutritional benefits. Evidence that these additions improve results is limited, and compounded products are not FDA-approved.
Read articleThere is no single alcohol rule for GLP-1 medications, but alcohol overlaps with known risks such as pancreatitis and low blood sugar. Early research suggests semaglutide may reduce alcohol craving, though that is not an approved use.
Read articleEvery weight loss method eventually levels off. The physiology behind plateaus, why GLP-1 medications delay them, and how to tell a true plateau from ordinary fluctuation.
Read articleResistance training is the single most effective way to protect muscle and bone while losing weight. Here is what the guidelines recommend, what the research shows, and how to begin safely without a gym background.
Read articleBoth are weekly injectables that act on gut hormone receptors, but they are not the same molecule. Here is how they differ in mechanism, trial results, side effects and regulatory status.
Read articleLosing weight means losing some muscle along with fat. What the research says about how much, why it matters, and the two levers that protect lean mass: protein intake and resistance training.
Read articleObesity behaves like a chronic condition, and the trial data on stopping GLP-1 medications show why. What long-term management looks like, what a licensed provider monitors, and how to think about maintenance.
Read articleWhen appetite drops, the quality of each meal matters more. A practical guide to protein, fiber, fluids and micronutrients while taking a GLP-1 medication, drawn from published clinical guidance.
Read articleNausea, constipation, fatigue and other frequent side effects of GLP-1 medications, what the trial data say about how common they are, and practical strategies people use with their provider's guidance.
Read articleReduced thirst, smaller meals and occasional vomiting or diarrhea can add up to dehydration. What the science says about fluid needs, how GLP-1 medications change the picture, and simple habits that help.
Read articleGLP-1 medications copy a hormone your gut already makes. Here is what that hormone does, how the medications change appetite and digestion, and which products are FDA-approved versus compounded.
Read articleAn honest look at what GLP-1 medications have been shown to do, what the labels warn about, and the open questions that a licensed provider should talk through with you.
Read article